Chinese drug research firms are altering project plans, stockpiling supplies, and considering testing locally to soften the blow of US-China trade tensions, Reuters reported Wednesday, citing sources with knowledge of the matter.
Companies such as WuXi AppTec (HKG:2359, SHA:603259) and WuXi Biologics (HKG:2269) help pharmaceutical giants such as Pfizer and AstraZeneca with their research through the use of imported clinical samples, equipment, and chemicals, Reuters said.
Apprehensions regarding difficulties of accessing US supply chains are driving Chinese biotech firms to avoid, pause, or delay project start times, the report said.
Chinese firms are also mulling testing US clinical samples in the US instead of sending them to China for further studies, although that could raise costs, Reuters reported, citing the sources.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。